SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
| 49950 | |
| 48300 | |
| - | |
| 49950 | |
| 47800 | |
| 43650-73700 | |
| 3 699 259 M | |
| 76 828 K | |
| 371 479 M | |
| -290 | |
| 1.178 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
SK bioscience invested USD 3 million in FinaBio, a U.S. company specializing in next-generation conjugate vaccine technology. With the agreement, SK bioscience expects to improve the immunogenicity an...
SK bioscience completed the acquisition of German CDMO company IDT Biologika with over a century of history that enables immediate expansion in revenue and infrastructure. The company aims to double s...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
